• +1-646-491-9876
    • +91-20-67278686

    Search

    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689431
    • Category Healthcare
    • No. of Pages 176
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

    Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 8, 2, 16 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 7
    Publisher Report Coverage 7
    Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8
    Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 29
    Allergan Plc 29
    Arisaph Pharmaceuticals Inc 29
    AstraZeneca Plc 30
    Betagenon AB 30
    Bird Rock Bio Inc 31
    Can-Fite BioPharma Ltd 31
    Cerenis Therapeutics Holding SA 32
    Conatus Pharmaceuticals Inc 32
    Corcept Therapeutics Inc 33
    CymaBay Therapeutics Inc 33
    Daewoong Pharmaceutical Co Ltd 34
    Dimerix Bioscience Pty Ltd 34
    Dr. Falk Pharma GmbH 35
    DURECT Corp 35
    Enanta Pharmaceuticals Inc 36
    Eternygen GmbH 36
    Galmed Pharmaceuticals Ltd 37
    Gemphire Therapeutics Inc 37
    Genfit SA 38
    Gilead Sciences Inc 38
    Huons Co Ltd 39
    Immuron Ltd 39
    Kyorin Pharmaceutical Co Ltd 40
    Matinas BioPharma Holdings Inc 40
    Miyarisan Pharmaceutical Company Ltd 41
    NovaTarg Therapeutics Inc 41
    Pfizer Inc 42
    Renova Therapeutics Inc 42
    Sancilio & Company Inc 43
    TaiwanJ Pharmaceuticals Co Ltd 43
    TCM Biotech International Corp 44
    Zydus Cadila Healthcare Ltd 44
    Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 45
    (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 45
    (leucine + PDE5 Inhibitor) - Drug Profile 47
    AC-261066 - Drug Profile 48
    Aramchol - Drug Profile 49
    ARI-3037MO - Drug Profile 55
    AZD-4076 - Drug Profile 57
    C-10 - Drug Profile 59
    CBM-588 - Drug Profile 61
    cenicriviroc mesylate - Drug Profile 63
    CER-209 - Drug Profile 71
    CORT-118335 - Drug Profile 72
    dapagliflozin propanediol - Drug Profile 73
    DMX-300 - Drug Profile 80
    Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 81
    DUR-928 - Drug Profile 82
    DWP-10292 - Drug Profile 86
    EDP-305 - Drug Profile 87
    elafibranor - Drug Profile 88
    emricasan - Drug Profile 96
    FLB-12 - Drug Profile 104
    gemcabene calcium - Drug Profile 105
    GS-0976 - Drug Profile 109
    GS-9674 - Drug Profile 111
    HTD-1801 - Drug Profile 114
    HU-002 - Drug Profile 115
    IMM-124E - Drug Profile 116
    liothyronine sodium - Drug Profile 119
    MAT-8800 - Drug Profile 120
    MN-002 - Drug Profile 121
    naltrexone hydrochloride - Drug Profile 123
    Namacizumab - Drug Profile 125
    namodenoson - Drug Profile 126
    NLM-0100 - Drug Profile 131
    norursodeoxycholic acid - Drug Profile 132
    O-304 - Drug Profile 134
    oltipraz - Drug Profile 136
    PF-06835919 - Drug Profile 137
    RT-200 - Drug Profile 138
    RT-210 - Drug Profile 139
    saroglitazar - Drug Profile 140
    SC-410 - Drug Profile 142
    seladelpar - Drug Profile 143
    selonsertib - Drug Profile 147
    Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 149
    Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 150
    Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 151
    Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 152
    Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 153
    TCM-606F - Drug Profile 154
    tipelukast - Drug Profile 155
    Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 160
    Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 161
    Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 162
    Featured News & Press Releases 162
    Appendix 172
    Methodology 172
    Coverage 172
    Secondary Research 172
    Primary Research 172
    Expert Panel Validation 172
    Contact Us 172
    Disclaimer 173

    List of Tables

    Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H1 2017
    Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Arisaph Pharmaceuticals Inc
    AstraZeneca Plc
    Betagenon AB
    Bird Rock Bio Inc
    Can-Fite BioPharma Ltd
    Cerenis Therapeutics Holding SA
    Conatus Pharmaceuticals Inc
    Corcept Therapeutics Inc
    CymaBay Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    Dimerix Bioscience Pty Ltd
    Dr. Falk Pharma GmbH
    DURECT Corp
    Enanta Pharmaceuticals Inc
    Eternygen GmbH
    Galmed Pharmaceuticals Ltd
    Gemphire Therapeutics Inc
    Genfit SA
    Gilead Sciences Inc
    Huons Co Ltd
    Immuron Ltd
    Kyorin Pharmaceutical Co Ltd
    Matinas BioPharma Holdings Inc
    Miyarisan Pharmaceutical Company Ltd
    NovaTarg Therapeutics Inc
    Pfizer Inc
    Renova Therapeutics Inc
    Sancilio & Company Inc
    TaiwanJ Pharmaceuticals Co Ltd
    TCM Biotech International Corp
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments